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Background: To facilitate the use of fractional exhaled nitric oxide (FENO) as a clinical test,
FENO measurements need more clarification.
Aim: We sought to evaluate the yield of FENO measurement for the diagnosis of asthma and
identify the determinants of FENO in children.
Methods: Two hundred forty five consecutive steroid-naı¨ve patients aged 8e16 years with
symptoms suggestive of asthma were included. Children were evaluated using FENO measure-
ments, questionnaires, skin prick tests, spirometries, and methacholine challenge tests.
Results: Asthma was diagnosed in 167 children. The sensitivity, specificity, and positive (PPV)
and negative predictive values (NPV) of FENO measurements for the diagnosis of asthma at the
best cutoff value of 22 ppb were 56.9%, 87.2%, 90.5%, and 48.6%, respectively. At a cutoff
value of 42 ppb, specificity and PPV were all 100% but at the cost of very low sensitivity
(23.4%) and NPV (37.9%). Both atopy and asthma were identified as independent risk factors
associated with high FENO. The association of asthma with high FENO was found only in atopic
children because FENO was low in non-atopic children regardless of asthma status. Although
highest FENO was observed in atopic asthmatic patients, 28% of these patients had FENO values
lower than 22 ppb.
Conclusion: Atopic asthmatic patients with low FENO values and non-atopic asthmatic patients
were responsible for false-negative cases that might contribute to low sensitivity of FENO
measurements in diagnosing asthma. High specificity of FENO measurements may help identify
patients with atopic asthma among subjects with respiratory symptoms.
ª 2012 Elsevier Ltd. All rights reserved.269 6042; fax: þ82 43 264 6620.
.ac.kr (Y.-S. Hahn).
2 Elsevier Ltd. All rights reserved.
1104 S.-I. Woo et al.IntroductionThe diagnosis of asthma is usually based on symptoms,
pulmonary function tests, assessment of bronchodilator
response, and bronchial challenge tests.1 However,
neither symptoms nor the results of basic pulmonary
function tests can reflect ongoing airway inflammation.2,3
In addition, the relevance of bronchial challenge tests to
the degree of inflammation is not always consistent
although this test is a reliable tool for airway hyper-
responsiveness.4 Direct measurement of airway inflam-
mation is thus required and may be more appropriate for
the diagnosis of asthma.
FENO correlates with airway eosinophilia in induced
sputum, biopsy material, and bronchoalveolar lavage flu-
id.5e7 Therefore, FENO measurements may be a useful
monitoring tool for asthmatic airway inflammation,
without the practical difficulties associated with bron-
chial biopsy or sputum induction. Because FENO is
elevated in subjects with asthma compared with control
subjects,8,9 high FENO may be helpful in establishing the
correct diagnosis of asthma in patients. However,
although FENO measurements offer a step forward in the
assessment of asthma, the interpretation of FENO
measurements in patients with probable asthma needs to
be further clarified.
In this current study, our aim was to evaluate the diag-
nostic utility of FENO measurements as a test for asthma.
For this, we investigated the sensitivity, specificity and
predictive values of FENO measurements for diagnosing
asthma in a prospective manner in a group of consecutive
child patients with a possible diagnosis of asthma. We also
aimed to explore the combined effect of asthma and atopic
status on FENO levels in our study population.
Methods
Subjects
This study included 245 child patients 8e16 years of age
consecutively referred to the outpatient clinic of the
Chungbuk National University Hospital, Cheongju, Republic
of Korea, for evaluation of asthma. These children had
presented with nonspecific respiratory symptoms sugges-
tive of asthma including cough, wheezing, and shortness of
breath. In these patients, the diagnosis of asthma was
investigated by means of clinical assessments, FENO
measurements, spirometries, methacholine challenge
tests, and skin prick tests. FENO measurement was per-
formed first followed by spirometry and methacholine
challenge test. Participants with acute upper respiratory
tract infection were asked to return for testing 4 weeks
after resolution of symptoms. All of included patients did
not receive inhaled short-acting b2-agonists in the 8 h prior
to the measurements and were also not receiving a regular
treatment with controller medications for 3 months or
more before evaluation of FENO and lung function. The
Ethics Committee of Chungbuk National University Hospital
Institutional Review Board approved the study and written
informed consent was obtained from the parents of all
subjects.Study design
This study was performed prospectively to identify the
determinants of FENO and evaluate the validity of FENO
measurements for diagnosis of asthma in a consecutive
group of children who had symptoms suggestive of asthma.
Patients or their parents were requested to answer the
ISAAC (International Study of Asthma and Allergies in
Childhood) questionnaire.10 In all patients, FENO
measurement, spirometry, and methacholine challenge
test were performed respectively by same operators who
were blinded to the patient history and diagnosis. Partici-
pants were defined as atopic when they had at least one
positive skin prick test to aeroallergens. Atopic and non-
atopic subjects were subdivided for further analysis into
two subgroups based on the presence of asthma. According
to the National Asthma Education and Prevention Program
(NAEPP) guidelines,1 the diagnosis of asthma was estab-
lished in subjects with a relevant symptom history when
they had reversible airflow obstruction (12% improvement
in FEV1 in response to inhaled b2-agonist) and/or airway
hyperresponsiveness (methacholine PC20 8 mg/mL). The
diagnosis of asthma was made by the same investigator who
was blinded to the results of FENO measurements and skin
prick tests.
FENO measurement
FENO was measured by chemoluminescence using an online
nitric oxide monitor (NIOX MINO; Aerocrine AB, Solna,
Sweden), according to the ERS/ATS guidelines11 and
expressed as parts per billion (ppb). The children were
instructed to avoid eating, drinking, and strenuous exercise
2 h before FENO measurements. After inhalation of ambient
air through a nitric oxide scrubber to total lung capacity,
subjects then exhaled against expiratory resistance to
exclude nasal air. Exhalation times were 10 s with a 2-min
analysis period. Repeated exhalations (two values that
agree within 5% or 3 that agree within 10%) were performed
without a nose clip at a constant flow rate of 50 mL/s.
Pulmonary function testing
Lung function tests were performed with spirometer (Sen-
sormedics Vmax 229, Yorba Linda, CA, USA) in accordance
with ATS/ERS recommendations.12 The following variables
were obtained from the best of 3 reproducible forced
expiratory maneuvers: FVC, FEV1, FEF25e75, and FEV1/FVC
ratio. Percent predicted values were calculated based on
Third National Health and Nutrition Examination Survey
(NHANES III).13 Methacholine PC20 and maximum broncho-
dilator responses to salbutamol (400 mg) were measured in
all study participants according to ATS/ERS guidelines.12,14
Methacholine was inhaled in doubling concentrations
ranging from 0.05 to 16 mg/mL at 5-min intervals according
to a standardized procedure. FEV1 was measured after 2-
min tidal breathing through a calibrated nebulizer (model
646; Devilbiss Health Care Inc, Somerset, PA). The chal-
lenge with inhaled methacholine was performed until FEV1
decreased by at least 20% from baseline FEV1 to determine
methacholine PC20.
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Skin prick testing was performed with common aero-
allergens including house dust mite (Dermatophagoides
farinae and Dermatophagoides pteronyssinus), Alternaria,
Cladosporium, Aspergillus, Mucor, Penicillium, dog, cat,
cockroach, mugwort, timothy, ragweed, birch, alder,
Hazel, plane tree, and oak. The longest and orthogonal
diameters of the wheal were measured and those with
a mean wheal of at least 3 mm were considered positive.
Statistical analysis
Demographic and clinical data were presented as means and
standard deviation (SD) for continuous variable. Differences
among patients according to atopy, asthma, or FENO level
were compared by using c2, ManneWhitney, or t tests, as
appropriate. FENO values were logarithmically transformed
to assumeanormal distribution andexpressed as a geometric
means with 95% Confidence Intervals (CIs). A receivereop-
erator characteristic (ROC) curvewas plotted,which allowed
a graphical representation of sensitivity and specificity in
order to view the best cutoff value for the diagnosis of
asthma. Factors possibly affecting FENO were analyzed by
simple linear regression and student’s t-test was carried out
to assess associations between log-transformed FENO values
and the categorical variables. For multivariate analysis,
multiple linear regression used an enter selection method
with variables that had a p-value<0.1 in univariate analyses
and Student’s t-test for consideration of inclusion into the
model. A p-value of <0.05 was considered significant.
Statistical analyses were performed using the commercially
available SPSS for Windows program (version 14.0; SPSS Inc.,
Chicago, IL, USA).Results
Patient characteristics
Among 245 study subjects who were included in this study,
163 (67%) were boys and 82 (33%) were girls. Symptoms for
which patients were referred were cough (n Z 56),
wheezing episodes (n Z 49), dyspnea (n Z 39), cough and
wheeze (nZ 34), dyspnea and wheeze (nZ 32), cough and
dyspnea (n Z 24), dyspnea on exercise (n Z 11). A diag-
nosis of asthma could be established in 167 subjects. Of
these subjects, airway hyperresponsiveness and reversible
airflow obstruction were detected in 157 and 40 subjects,
respectively. Geometric mean (GM) FENO value in asthmatic
patients was 23.4 parts per billion (ppb) (95% CI,
20.9e26.2 ppb) which was higher than 12.6 ppb (95% CI,
10.9e14.5 ppb) in non-asthmatic children (p < 0.001). The
patient characteristics of atopic asthmatic, atopic non-
asthmatic, non-atopic asthmatic and non-atopic non-
asthma groups are shown in Table 1. The atopy rate among
boys was 82% which was significantly higher than 67% among
girls (p Z 0.008). There was no difference in age, anthro-
pometric values, and exposure to parental smoking
between groups. GM FENO value in the atopic subjects was
significantly higher than those without atopy regardless ofasthma status (p < 0.001). In atopic subjects, GM FENO
value was significantly higher in asthmatic patients than
that in non-asthmatic subjects (p < 0.001). In contrast, in
non-atopic patients, GM FENO in asthmatic patients was not
different from that in subjects without asthma (pZ 0.627).
The pretest probability of having asthma in our study pop-
ulation was 167 of 245 patients (67%).
Diagnostic yield of FENO measurement
We constructed a ROC curve to determine the sensitivity
and specificity of FENO for diagnosing asthma (Fig. 1a). With
asthma used as the dependent variable, the area under the
ROC curve (AUC) for FENO was 0.76 (95% CI, 0.70e0.82,
p < 0.001). The values of sensitivity, specificity, positive
and negative predictive value, and accuracy for cutoff
values of FENO level were listed in Table 2. The sum of the
sensitivity and specificity for the cutoff values of FENO was
calculated and the highest sum was observed at 22 ppb,
which provided 56.9% sensitivity, 87.2% specificity, 90.5%
PPV, and 48.6% NPV, respectively. Thus, at this cutoff point,
sensitivity and NPV were relatively low compared with
specificity and PPV which appeared acceptable for the
diagnosis of asthma. At a cutoff of 42 ppb, specificity and
PPV were all 100% but at the cost of very low sensitivity
(23.4%) and NPV (37.9%).
We also aimed to determine a cutoff value of FENO
measurements only in atopic subjects for the diagnosis of
asthma (Fig. 1b). In these subjects, the diagnostic perfor-
manceofFENOmeasurements (AUCZ0.85,95%CI,0.79e0.90;
p < 0.001) was better than in total study participants. The
highest combination of the sensitivity and specificity was also
observed at 22 ppb. At this cutoff value, the sensitivity, spec-
ificity, PPV, and NPV were 72.1%, 85.0%, 91.2%, and 58.6%,
respectively. When 129 patients diagnosed of having atopic
asthma in our studywere stratified into high (>21 ppb) and low
(21 ppb) groups, 93 (72%) and 36 (28%) patients belonged to
the high and low FENO groups, respectively.
Univariate and multivariate analyses of factors
associated with FENO levels
We used GM FENO for linear regression analyses. At first, we
performed univariate analyses to investigate the relation-
ship of FENO levels to the explanatory variables listed in
Table 3. There were significant differences in FENO levels
among subjects grouped by asthma, atopy, or gender.
The risk factors in Table 3 with a p-value <0.10 were
entered in multivariate analyses to estimate which factors
were independently related to the increased FENO levels.
This regression model explained 35.4% of total variation in
FENO levels for subjects in our population. Based on
regression coefficients, atopy was the strongest contributor
to the increased FENO levels (Table 4). Asthma and male sex
were also significantly associated with high FENO after
adjustment of other factors.
Discussion
We found that FENO in patients with objective evidence of
asthma was significantly higher than that in patients with
Table 1 Patient characteristics.
Characteristics Non-atopy Atopy
Non-asthma (n Z 18) Asthma (n Z 38) Non-asthma (n Z 60) Asthma (n Z 129)
Age (years) 11.4  2.0 11.6  2.7 12.6  2.6 11.7  2.4
Sex (Male: Female) 9:9 20:18 42:18 92:37
Height (cm) 147.9  14.7 143.8  12.3 152.2  13.5 147.3  14.2
Body weight (kg) 46.1  19.9 40.8  12.4 46.1  15.0 42.5  13.3
Body mass index 20.3  5.4 19.4  3.5 19.4  3.9 19.1  3.2
Passive smoking (%) 5 (28) 12 (32) 22 (37) 32 (25)
GM FENO (ppb, 95% CI) 9.7 (7.1e13.3) 10.6 (8.6e13.0) 13.6 (11.6e15.9)
b 29.6 (26.6e32.8)a
Log2PC20 (mg/dL) >3 1.2  1.7 >3 0.9  1.7
a Atopy with asthma vs others: all p < 0.001.
b Atopy without asthma vs Non-atopy with/without asthma: all p < 0.05.
1106 S.-I. Woo et al.non-asthmatic conditions. However, there remained
a considerable amount of overlap between the FENO levels
in the asthmatic and non-asthmatic group. In particular,
non-atopic asthmatic patients and substantial proportion of
atopic asthmatic patients presented low levels of FENO.
Sensitivity and specificity of FENO measurements in
previous clinic-based studies appear to be acceptable for
discriminating asthma from non-asthma.15e18 However, it is
important to remember that low FENO values do not
exclude the diagnosis of asthma because FENO levels are
normal, especially in non-atopic subjects.19 Also in our
study, FENO levels for non-atopic asthmatic patients were
not different from those for the non-atopic non-asthmatic
group. Furthermore, 28% of atopic patients with asthma
had FENO levels lower than 22 ppb which was the threshold
to strike an appropriate balance between sensitivity and
specificity of FENO measurements in our study population.
Therefore, the inclusion of the false-negative cases
contributed to low sensitivity of FENO measurements in our
study, implying the limitation of FENO measurements in
diagnosing asthma. On the other hand, FENO measurement
was associated with acceptable values of specificity and
PPV for the diagnosis of asthma at the FENO cutoff value
greater than 21 ppb. In addition, FENO levels above 41 ppbFigure 1 Receivereoperator characteristic (ROC) curves indica
predicting asthma in (a) total study population and (b) atopic subjmight be able to exclude non-asthmatic conditions because
specificity and PPV of FENO at a cutoff above this level were
all 100%. Furthermore, our study showed higher AUC in
atopic subjects than in total study participants, suggesting
better discriminative accuracy of FENO measurements in
atopic subjects than in the general population including
non-atopic subjects.
Heterogeneity of FENO levels in atopic asthmatic
patients reflects that this group of patients might be
different in severity or phenotype of airway inflammation.
It is possible that FENO levels in atopic asthmatic patients
with milder eosinophilic airway inflammation may fluctuate
and be accidentally low on snapshot measurements. The
difference of inflammatory phenotype may be another
possible explanation for heterogenous FENO levels in atopic
asthma patients. Some atopic asthmatic subjects predom-
inantly have neutrophilic airway inflammation and react to
allergen with marked airway influx of neutrophils,20,21
implying low FENO levels in this group of atopic asthmatic
patients. However, the relationship between inflammatory
phenotype and FENO levels will necessitate further
investigation.
Previous studies have shown mixed results concerning
interrelationship among asthma, atopy and FENO. Someting the sensitivity and specificity of FENO measurements for
ects.
Table 2 Diagnostic yield of FENO measurements.
FENO cutoff
values
Sensitivity Specificity PPV NPV Accuracy
>50 14.4 100.0 100.0 35.3 41.6
>45 17.4 100.0 100.0 36.1 43.7
>41 23.4 100.0 100.0 37.9 47.8
>40 24.6 98.7 97.6 37.9 48.2
>35 32.3 98.7 98.2 40.5 53.5
>30 42.5 94.9 94.7 43.5 59.2
>25 49.7 92.3 93.3 46.2 63.3
>24 50.3 91.0 92.3 46.1 63.3
>23 51.5 91.0 92.5 46.7 64.1
>22 53.9 87.2 90.0 46.9 64.5
>21 56.9 87.2 90.5 48.6 66.5
>20 60.5 80.8 87.1 48.8 66.9
>15 71.9 66.7 82.2 52.5 70.2
>10 80.2 44.9 75.7 51.5 69.0
>5 94.0 14.1 70.1 52.4 68.6
PPV: positive predictive value, NPV: negative predictive value.
Table 4 Mutlivariate model predicting logarithmic FENO
in study population.
Characteristics Coefficient (95% CI) p-value
Sex 0.094 (0.022e0.166) 0.010
Asthma 0.268 (0.196e0.339) <0.001
Atopy 0.332 (0.251e0.413) <0.001
CI: Confidence interval.
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dren independent of asthma status,22e24 while others have
found higher FENO levels in atopic subjects with concomi-
tant asthma than those with atopy alone.25e27 In our study,
although atopy was most strongly associated with
increased FENO, asthma remained an independent factor
contributing to high FENO after adjusting for atopy.
Furthermore, asthma in atopic patients was associated
with higher levels of FENO, which was not found in non-
atopic asthmatic patients, suggesting that coexisting
asthma may contribute to the additional increase of FENO
only in atopic subjects. Thus, asthma-related additional
increase of FENO in atopic patients is thought to render
FENO measurement highly specific for atopic asthma. In our
study, the proportion of patients with atopic asthma wasTable 3 Univariate correlation of factors associated with FENO
Categorical variables n (yes/no) GM FEN
Yes
Sex (Male) 163/82 21.5 (1
Asthma 167/78 23.4 (2
Atopy 189/56 23.1 (2
Passive smoking 71/174 20.9 (1
Continuous variables Mean  SD
Age (years) 11.7  2.2
Anthropometric measurement
Height (cm) 148.0  13.9
Weight (kg) 43.4  14.2
Body mass index 19.3  3.6
Pulmonary function
FVC % predicted 88.9  11.7
FEV1 % predicted 87.6  11.6
FEV1/FVC 88.0  7.7
FEF25e75 % predicted 84.0  22.1
CI: Confidence interval.high at 53%, which seems to be appropriate when inter-
preting the performance characteristics of FENO measure-
ment. We speculate that this high proportion of patients
with atopic asthma may be apt to evaluate the influence of
atopy and asthma on FENO.
Sex-specific differences in asthma have been expressed
as a higher prevalence of asthma in boys before
puberty28,29 and also been reported for numerous asthma-
related traits including allergic sensitization and develop-
mental cytokine response profiles.30,31 In our study, the
proportions of boys in subjects with atopic asthma or atopy
alone were more than two times larger than those of girls.
These were similar to the proportion of boys in regularly
followed-up patients attending our outpatient clinic for
atopic asthma. In addition, similar to previous studies that
reported higher FENO levels in males,
32,33 we also found the
contribution of male sex to higher FENO levels although the
effect was less strong than atopy and asthma.
There are several limitations to our study. First, our
study included children with symptoms suggestive of
asthma, which could limit the generalizability of our
results. We speculate that high proportion of atopic
subjects in our study population could mask the influence
of anthropometric and spirometric values, exposure to
parental smoking, and age. Hence, our study has a possi-
bility to yield misleading conclusions in the analyses of the
influence of above confounding factors. Second, we did not.
O (ppb, 95% CI)
No p-value
9.3e24.0) 15.3 (12.8e18.3) 0.001
0.9e26.2) 12.6 (10.9e14.5) <0.001
0.9e23.5) 10.3 (8.7e12.1) <0.001
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FENO in patients with rhinitis have been reported previ-
ously22,34 but contrasts with the result of other investigator
who found that rhinitis was not significantly associated with
FENO levels.
27 Contamination of the exhaled air by NO-rich
air from the nasal cavity is unlikely, as the soft palate
elevates when expiration is performed against a resis-
tance.35,36 This suggests that high FENO in patients with
allergic rhinitis results from an increased production of NO
in the lower airways. Thus, it is certainly plausible that the
influence of rhinitis on the FENO levels may be limited.
In summary, high FENO values could discriminate asthma
from non-asthmatic conditions although normal FENO
values did not exclude the diagnosis of asthma. FENO levels
within our study population were influenced by the pres-
ence of atopy, such that significantly elevated FENO levels
were not found in the absence of atopy. In addition,
coexisting asthma contributed to the additional increase of
FENO values only in subjects with atopy. Therefore, the
asthma-related increase of FENO in atopic patients is
thought to render FENO measurement highly specific for
atopic asthma and is able to allow physicians to use FENO
measurement for diagnosis of atopic asthma in children
with respiratory symptoms suggestive of asthma.
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